Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second most common
cause of death within the next 10 years. The prognosis for this disease is poor despite …

Pancreatic cancer is a highly lethal disease, for which mortality closely parallels incidence.
Most patients with pancreatic cancer remain asymptomatic until the disease reaches an …

For pancreatic solid lesions, ESGE recommends performing endoscopic ultrasound (EUS)-
guided sampling as first-line procedure when a pathological diagnosis is required …

BACKGROUND Cell‐free circulating tumor DNA (ctDNA) in serum has been considered to
be a useful candidate for noninvasive cancer diagnosis. The current study was designed to …

Mutation of the KRAS oncogene in pancreatic cancer is responsible for permanent activation
of the P21 RAS protein and the cascade of signalling pathways. Consequently, multiple …

Biomarkers play an essential role in the management of patients with invasive cancers.
Pancreatic ductal adenocarcinoma (PDC) associated with poor prognosis due to advanced …

Cell‐free circulating tumor DNA (ctDNA) in plasma has been used as a potential
noninvasive biomarker for various tumors. Our study was performed to evaluate the clinical …

The fourth part of the European Federation of Societies for Ultrasound in Medicine and
Biology (EFSUMB) Guidelines on Interventional Ultrasound describes general aspects of …

Background: KRAS G12D mutation subtype is present in over 40% of pancreatic ductal
adenocarcinoma (PDAC), one of the leading global causes of cancer death. This …

Tissue acquisition using EUS has considerably evolved since the first EUS-FNA was
reported 25 years ago. Its introduction was an important breakthrough in the endoscopic …